EXEL: Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer

New alert via PocketInfo for EXEL:

Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer

Press Releases: http://www.exelixis.com/investors-media/press-releases
SEC Filings: http://www.exelixis.com/investors-media/sec-filings
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8